Background: Lung cancer is the leading cause of cancer-related death. NSCLC accounts for 80-90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3-7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FDA. Case: We present a case of a 17-year-old male with metastatic treatment-naïve ALK-positive adenocarcinoma. He was treated with crizotinib and obtained a prolonged response with PFS of 33 months. Conclusion: Crizotinib can be extremely effective in adolescents with treatment-naïve ALK-positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.
Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer / Megaro, Giacomina; Miele, Evelina; Spinelli, Gian Paolo; Alessi, Iside; Del Baldo, Giada; Cozza, Raffaele; Russo, Ida; De Pasquale, Maria Debora; Cefalo, Maria Giuseppina; Tomà, Paolo; Carai, Andrea; Di Ruscio, Valentina; De Ioris, Maria Antonietta; Mastronuzzi, Angela. - In: CANCER REPORTS. - ISSN 2573-8348. - (2022), p. e1483. [10.1002/cnr2.1483]
Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer
Megaro, Giacomina;Miele, Evelina;Spinelli, Gian Paolo;Del Baldo, Giada;De Pasquale, Maria Debora;Di Ruscio, Valentina;Mastronuzzi, Angela
2022
Abstract
Background: Lung cancer is the leading cause of cancer-related death. NSCLC accounts for 80-90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3-7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FDA. Case: We present a case of a 17-year-old male with metastatic treatment-naïve ALK-positive adenocarcinoma. He was treated with crizotinib and obtained a prolonged response with PFS of 33 months. Conclusion: Crizotinib can be extremely effective in adolescents with treatment-naïve ALK-positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
